Dermatology Billing Benchmarks for 2026

Specialty-specific benchmarks are what every practice wants and what nobody publishes. MGMA's values sit inside licensed products and are not public; HFMA's MAP Keys publish KPI definitions and equations but no target values, so any denial or clean-claim target attributed to HFMA is misattributed. That leaves a short list of freely published, general physician-practice figures. The table below is what we check when we review a dermatology practice's revenue cycle, with what each figure is actually sourced to — and an explicit blank where nothing is.

Two cautions on how to read that table. First, every figure in the "what is published" column is practice-management guidance rather than a measurement, except the two MGMA rows — and guidance with no sample behind it tells you what someone thinks good looks like, not what your peers actually do. Second, a dermatology practice that is heavy on Mohs and pathology will carry a different A/R profile than a general medical-derm clinic, because surgical pathology and Mohs reimbursement cycles run longer, so your own trailing twelve months is a better comparator than any of these. Of the mechanisms below, the one that moves a dermatology denial rate hardest is modifier 25 on same-day procedure-plus-E/M claims — which is why it gets its own section.

Benchmarks become real when you translate them into dollars. Here is the math on a single metric — clean claim rate — for a mid-size dermatology group.

Assumptions, all of them yours to change: 1,400 claims per month, an average dermatology claim value of $185 (a blend of office E/M, biopsies, destructions and the occasional Mohs/path line), and a practice running a 92% clean claim rate that wants to reach 95%. The 95% is not a published benchmark — no free source publishes one — it is simply the target this practice set.

The gap. At 92%, 8% of claims (112 per month) fail first-pass adjudication; at 95%, only 5% (70 claims) would. The 3-point gap means 42 extra claims rework every month that should have gone out clean.

The cost. The most-cited rework figure in the industry is MGMA's $25.20 cost to rework a denied claim, read 17 September 2026. Note the population before you use it: the figure traces to Change Healthcare's 2020 Revenue Cycle Denials Index, an analysis of 102 million claims from more than 1,500 hospitals (July 2019–June 2020), not physician practices — and it should be quoted only with its limitation attached, because MGMA states it with no population, denominator, sample or data year behind it. At $25.20, those 42 extra rework claims cost about $1,058 per month, or roughly $12,700 a year in pure labor. Your own number beats any published one here: time a rework end to end and multiply by your loaded hourly rate. On top of the labor sit the cash-flow delay and the share of reworked claims that never clear the timely-filing window — we have not seen a published benchmark for that share and do not quote one.

The lesson is the one that holds across every benchmark post: the cheapest claim is the one that goes out clean the first time. A scrubber rule that catches a missing modifier 25 costs nothing per claim once configured; a corrected-claim cycle costs real labor and delays cash. You can model your own numbers with our billing cost calculator and denial rate calculator.

Dermatology revenue concentrates in a relatively small set of CPT codes, and understanding how they bill explains where the denials come from. The codes below are the workhorses; reimbursement varies by Medicare Administrative Contractor (MAC) locality and by commercial contract, so the figures here describe the basis rather than a guaranteed dollar — always verify against the current CMS Physician Fee Schedule (PFS) for your locality and your payer contract.

Skin biopsy (11102-11107). This family replaced the old single biopsy codes in 2019 and is now technique- and quantity-based. 11102 is a tangential biopsy (first lesion); 11104 is a punch biopsy (first lesion); 11106 is an incisional biopsy (first lesion). The add-on codes 11103, 11105, and 11107 report each additional lesion of the same technique. A frequent denial source is mismatching the add-on to the base code or billing a biopsy on the same lesion that was then destroyed or excised in the same session (bundling territory).

Destruction of premalignant lesions (17000-17004). 17000 is destruction of the first premalignant lesion (for example, actinic keratosis); 17003 is each additional lesion from the 2nd through the 14th; 17004 is destruction of 15 or more premalignant lesions. Miscounting lesions or billing 17004 alongside 17000/17003 is a classic edit failure.

Benign/malignant lesion destruction (17110-17111, 17260-17286). 17110 covers destruction of up to 14 benign lesions; the 17260-series covers destruction of malignant lesions by anatomic site and size.

Mohs micrographic surgery (17311-17315). 17311 is the first stage, head/neck/hands/feet/genitalia, up to 5 tissue blocks; 17312 is each additional stage of that anatomic group. 17313 is the first stage of the trunk/arms/legs; 17314 is each additional stage there. 17315 is the add-on for each additional block beyond 5 per stage. Mohs has its own bundling rules — the same physician acts as surgeon and pathologist, so a separate pathology code is generally not billable for the Mohs specimen, and an E/M on the same day usually requires modifier 25 with a clearly separate, documented reason.

Pathology (88304, 88305, 88312, 88321). Skin specimens are most often 88305 (Level IV surgical pathology, the dominant derm-path code); special stains and consults carry their own codes. Pathology lines extend the A/R cycle and are a common coordination point between the practice and an outside lab — the boundary where dermatology billing meets laboratory billing services.

E/M (99202-99215). Office visits billed alongside a same-day procedure are the single biggest modifier-25 battleground in dermatology — covered in detail below.

If your dermatology denial rate has drifted above your own trailing average, modifier 25 is the first place to look. Dermatology bills a significant, separately identifiable E/M service on the same day as a minor procedure more than almost any other specialty, and modifier 25 is the modifier that tells the payer the E/M was genuinely separate from the procedure's inherent pre- and post-service work.

When modifier 25 is correct. A patient presents for a skin-check, the dermatologist evaluates a new and unrelated complaint requiring a separate workup, and in the same visit destroys an actinic keratosis. The E/M (99213, say) carries modifier 25 to signal it was significant and separately identifiable from the destruction (17000). The documentation must support a distinct E/M: a separate history, exam, and medical decision-making beyond the work inherent to the procedure.

When it is wrong. If the only reason for the visit was the procedure — the patient came in specifically to have a known lesion frozen — appending modifier 25 to a thin E/M is exactly the pattern that triggers payer scrutiny and post-payment audit. Payers (especially Medicare Advantage and several large commercials) audit modifier 25 aggressively, and some have rolled out automatic reductions or reviews on high-frequency 25 use.

The benchmark impact. A modifier 25 denial typically surfaces as CO-97 (E/M bundled into the procedure allowance) or as a flat CO-4 (modifier missing/inconsistent). When 25 is omitted on a legitimately separate E/M, you lose the E/M payment; when it is overused without documentation, you invite audits and recoupments. Either way it moves your denial rate the wrong direction. For the full decision framework, see our guide on when to use modifier 25 and the modifier 25 glossary entry.

The other modifier dermatology leans on is modifier 59 / the X-modifiers (XE, XS, XP, XU) to unbundle distinct procedures on the same day — for example a biopsy of one lesion and destruction of a separate lesion at a different anatomic site. Use the most specific X-modifier the documentation supports; our modifier 59 vs X-modifiers guide covers the choice.

A handful of CARC codes account for most of dermatology's preventable denials. The table maps each to its dermatology-specific trigger and the fix. Read the exact CARC and RARC on your 835 ERA — the group code (CO vs PR) determines who owns the balance.

The single highest-yield prevention move in dermatology is a front-end edit that flags any claim with both an E/M and a same-day procedure and forces a modifier-25 documentation check before submission. That one rule prevents the largest preventable denial category in the specialty. For why there is no specialty-level denial benchmark to compare yourself against, see our denial rate by specialty page, which sets out what is published, what is not, and which bands we withdrew.

Days in A/R measures how long it takes the practice to collect what it has billed: divide total accounts receivable by average daily charges (typically the trailing 3-month charge average divided by 90). AAFP's Practice Finances guidance, read 17 September 2026, says days in A/R should stay below 50 at minimum, with 30 to 40 preferable — guidance, with no sample or denominator behind it, and no dermatology-specific version of it exists. The one freely published measurement nearby is MGMA's A/R aging stat, read 17 September 2026, which puts the median share of total A/R over 120 days at 13.54% for multispecialty practices in 2021. A Mohs- and pathology-heavy practice will run slightly higher because surgical pathology and multi-stage Mohs claims have longer adjudication cycles and more coordination with outside labs — so judge your number against your own service mix, not a one-size band. If your days in A/R is climbing above 45, the cause is usually one of three things: a denial backlog that is not being worked, slow patient-balance collection on high-deductible plans, or a credentialing/enrollment gap that is holding claims for a provider who is not yet active with a payer.

Collection rate measures how much of the contractually allowed amount you actually collect, after legitimate adjustments: net payments divided by (charges minus contractual adjustments). AAFP's Practice Finances guidance, read 17 September 2026, puts the adjusted collection rate at 95% minimum and the average at 95% to 99% — watch the metric name, because the "net collection rate should be 95-98%" version circulating online is that same guidance with the metric renamed and the range shifted. No free source publishes an observed net-collection-rate median for physician practices, and none publishes a dermatology one. Below 95% generally means earned money is being left on the table — usually to unworked denials, timely-filing write-offs, or under-collected patient balances. Whichever name you use, this is the truest single measure of revenue-cycle effectiveness, because unlike gross collection rate it is not distorted by your charge master.

To move both numbers: work denials within 7-14 days of receipt, keep an aging worklist that prioritizes high-dollar Mohs and pathology claims, collect patient responsibility at or before the point of service, and close enrollment gaps before a new provider starts seeing patients. You can pressure-test your own figures with our collection rate calculator, and the mechanics are broken down in net collection rate vs gross collection rate and days in A/R formula and benchmark.

Two dermatology-specific workflows quietly stretch the revenue cycle beyond what the headline denial rate shows.

Prior authorization is the bigger one. Biologic therapies for psoriasis and atopic dermatitis, photodynamic therapy, certain lasers, and some higher-cost procedures frequently require prior auth, and a missing or expired auth produces a CO-197 denial that is entirely preventable. The benchmark practice verifies auth requirements at scheduling, secures the auth before the date of service, documents the auth number on the claim, and tracks auth expiration dates so a renewal does not lapse mid-treatment. When a CO-197 does land, the fix is to attach proof the auth was obtained and appeal — but the win is preventing it. Robust prior authorization services own this workflow end to end; the glossary entry on prior authorization covers the mechanics.

Pathology coordination is the quieter one. When the practice sends specimens to an outside lab, the global-versus-technical-versus-professional split and the handoff between practice and lab create timing gaps and occasional duplicate or mismatched billing. The benchmark fix is a clear protocol for which entity bills which component, a reconciliation step that matches every specimen to a path result and a claim, and a worklist that does not let pathology lines age silently. Because 88305 and its siblings carry meaningful dollar value and longer cycles, letting them drift is a direct hit to days in A/R.

Both of these are why a dermatology practice can post a benchmark-looking denial rate and still run a sub-par days in A/R: the denials are fine, but the cash is slow. Measuring both metrics together is the only way to see the whole picture.

When a dermatology practice falls short of these benchmarks, the remediation sequence is consistent. Work it in this order, because each step compounds the next.

1. Fix the front end first (clean claim rate). Turn on a scrubber rule that flags every same-day E/M-plus-procedure claim for a modifier-25 documentation check, validate lesion counts against units on the 17003/17004 and 11103/11105/11107 add-ons, and run real-time eligibility before every visit. This single layer prevents the largest share of derm denials. Set the clean-claim target yourself from your trailing twelve months — no free source publishes one.
2. Close the modifier 25 / modifier 59 documentation loop. Add EHR template prompts that capture the separate-E/M reason and the distinct-lesion/site language at the point of care, not at appeal time. Documentation created at the encounter survives audit; documentation retrofitted at appeal usually does not.
3. Own prior authorization proactively. Build an auth-required code list, verify at scheduling, and track expirations — converting CO-197 from a recurring denial into a near-zero line.
4. Work denials and aged A/R on a clock. Categorize denials by CARC at intake, route each to the team that owns its root cause, and prioritize high-dollar Mohs and pathology claims in the aging worklist. This is the core of denial management services and accounts receivable follow-up services.
5. Close credentialing and enrollment gaps before they hold claims. A provider who sees patients before being active with a payer generates A/R that cannot be collected until enrollment completes — a hidden days-in-A/R inflator solved by disciplined provider enrollment services.
6. Measure monthly against the bands above. A benchmark is only useful if you track against it every month. When a metric drifts, the table tells you which lever to pull. Specialty-specific dermatology billing services run this loop continuously so the practice can focus on patients rather than claims.

The practices that hold these benchmarks are not doing anything exotic — they are running a disciplined front end, a documentation loop tied to the modifiers dermatology lives on, and a denial/A-R worklist on a tight clock. The economics favor that discipline overwhelmingly: prevention is nearly free per claim, and rework is not.